» Articles » PMID: 33201233

Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis Infection

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2020 Nov 17
PMID 33201233
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Ehrlichiosis cases in the US have increased more than 8-fold since 2000. Up to 57% of patients with ehrlichiosis require hospitalization and 11% develop a life-threatening complication; however, risk factors for serious disease are not well documented.

Objective: To examine risk factors associated with severe ehrlichiosis.

Design, Setting, And Participants: An analytic cross-sectional study of patients diagnosed with ehrlichiosis by polymerase chain reaction (PCR) between January 1, 2007, and December 31, 2017, was conducted in a single tertiary-care center in a region endemic for ehrlichiosis. Analysis was performed from February 27, 2018, to September 9, 2020. A total of 407 positive Ehrlichia PCR results were identified from 383 unique patients, with 155 unique patients meeting study criteria. Patients hospitalized at other institutions who had a positive Ehrlichia PCR performed as a reference test (n = 222) were excluded as no clinical data were available. Electronic medical record review was performed to collect demographic, clinical, laboratory, treatment, and outcomes data. Cases were excluded when there were insufficient clinical data to assess the severity of illness (n = 3) and when the clinical illness did not meet the case definition for ehrlichiosis (n = 3).

Exposures: Date of presentation, onset of symptoms, date of PCR testing, date of treatment initiation, site of care, age, birth sex, race/ethnicity, Charlson Comorbidity Index, trimethoprim with sulfamethoxazole use within the prior 2 weeks, and immunosuppression.

Main Outcomes And Measures: Requirement for intensive care unit (ICU) admission.

Results: Of the 155 patients who met inclusion criteria, 99 patients (63.9%) were men, and 145 patients (93.5%) identified as non-Hispanic White; median age was 50 years (interquartile range, 23-64 years). Intensive care unit admission was indicated in 43 patients (27.7%), 94 patients (60.6%) were hospitalized on general medical floors, and 18 patients (11.6%) received care as outpatients. In adjusted analysis, time to treatment initiation was independently associated with an increased risk for ICU admission (adjusted prevalence ratio [aPR], 1.09; 95% CI, 1.04-1.14; P < .001). Documentation of tick exposure was independently associated with a decreased risk for ICU admission (aPR, 0.54; 95% CI, 0.34-0.86; P = .01). There appeared to be a nonsignificant change toward a decreased need for ICU care among immunosuppressed persons (aPR, 0.51; 95% CI, 0.26-1.00; P = .05).

Conclusions And Relevance: This study suggests that delay in initiation of doxycycline therapy is a significant factor associated with severe ehrlichiosis. Increased recognition of infection by front-line clinicians to promote early treatment may improve outcomes associated with this increasingly common and life-threatening infection.

Citing Articles

Donor-Derived Ehrlichiosis Caused by Ehrlichia chaffeensis from Living Donor Kidney Transplant.

Scolarici M, Kuehler D, Osborn R, Doyle A, Schiffman E, Garvin A Emerg Infect Dis. 2025; 31(3):587-590.

PMID: 40023815 PMC: 11878297. DOI: 10.3201/eid3103.241723.


Contribution of Limited Molecular Testing to Low Ehrlichiosis Diagnosis in High Incidence Area, North Carolina, USA.

Siegler A, Ursery L, Giandomenico D, Miller M, Salzer J, Barbarin A Emerg Infect Dis. 2025; 31(2):281-287.

PMID: 39983688 PMC: 11845130. DOI: 10.3201/eid3102.240281.


Long-Term Protective Immunity against Infection Induced by a Genetically Modified Live Vaccine.

Madesh S, McGill J, Jaworski D, Ferm J, Liu H, Fitzwater S Vaccines (Basel). 2024; 12(8).

PMID: 39204029 PMC: 11360114. DOI: 10.3390/vaccines12080903.


Human monocytotropic ehrlichiosis-A systematic review and analysis of the literature.

Gygax L, Schudel S, Kositz C, Kuenzli E, Neumayr A PLoS Negl Trop Dis. 2024; 18(8):e0012377.

PMID: 39093857 PMC: 11324158. DOI: 10.1371/journal.pntd.0012377.


Neurological manifestations of ehrlichiosis among a cohort of patients: prevalence and clinical symptoms.

Iyamu O, Ciccone E, Schulz A, Sung J, Abernathy H, Alejo A BMC Infect Dis. 2024; 24(1):701.

PMID: 39020279 PMC: 11253485. DOI: 10.1186/s12879-024-09607-3.


References
1.
Kirkland K, WILKINSON W, Sexton D . Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis. 1995; 20(5):1118-21. DOI: 10.1093/clinids/20.5.1118. View

2.
Zientek J, Dahlgren F, McQuiston J, Regan J . Self-reported treatment practices by healthcare providers could lead to death from Rocky Mountain spotted fever. J Pediatr. 2013; 164(2):416-8. PMC: 4699435. DOI: 10.1016/j.jpeds.2013.10.008. View

3.
Dalton M, Clarke M, Holman R, Krebs J, Fishbein D, Olson J . National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg. 1995; 52(5):405-13. DOI: 10.4269/ajtmh.1995.52.405. View

4.
Cohen S, Yabsley M, Freye J, Dunlap B, Rowland M, Huang J . Prevalence of Ehrlichia chaffeensis and Ehrlichia ewingii in ticks from Tennessee. Vector Borne Zoonotic Dis. 2009; 10(5):435-40. DOI: 10.1089/vbz.2009.0058. View

5.
Allen M, Pritt B, Sloan L, Paddock C, Musham C, Ramos J . First reported case of Ehrlichia ewingii involving human bone marrow. J Clin Microbiol. 2014; 52(11):4102-4. PMC: 4313272. DOI: 10.1128/JCM.01670-14. View